* SCARCELL THERAPEUTICS *
2007 - IDF
Paris
www.scarcell-therapeutics.com Design, Drugs
Key words: Cell therapy project, Transplantation, Cardiovascular
Mission: to carry out an autologous gingival fibroblasts transplantation in order to repair injured tissues, in particular in the field of cardiovascular pathology (vascular prosthesis for abdominal aortic aneurysm, atherosclerosis,…) and others
Clients: undisclosed
postmaster@scarcell-therapeutics.com
Age: 5 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Spin-off |
Managing Dir.-CEO: Augier (Jean-Jacques) [legally as President, born 1953]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):
Note : URL not renewed in time (October 2009), still unavailable (February, May, October 2010, April 2011), but legally company still active | Turnover (M€) : 0.008 (2009)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Cardiovasc
Position : Proof-of-Concept
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2007 .04 | Company founded by Antoine Lafont (M.D., APHP, Directeur de l'Unité Inserm U849), Bruno Gogly (M.D., APHP, Inserm U849), Bernard Coulomb (Ph.D., Inserm U849), as a spin-off of AP-HP (Cochin hospital), in Paris Biotech center | ORGF | [0 year] | Actualisation / Updating: 9-May-2011 |
|
